VIR
Income statement / Annual
Last year (2025), Vir Biotechnology Inc's total revenue was $68.56 M,
a decrease of 7.61% from the previous year.
In 2025, Vir Biotechnology Inc's net income was -$437.99 M.
See Vir Biotechnology Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$68.56 M |
$74.21 M |
$86.18 M |
$1.62 B |
$1.10 B |
$76.37 M |
$8.09 M |
$10.67 M |
$2.71 M |
| Cost of Revenue |
$11.71 M
|
$15.40 M
|
$22.22 M
|
$161.81 M
|
$71.68 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$56.85 M
|
$58.80 M
|
$63.96 M
|
$1.45 B
|
$1.02 B
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0.83
|
0.79
|
0.74
|
0.9
|
0.93
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$432.80 M
|
$463.19 M
|
$550.92 M
|
$467.87 M
|
$442.20 M
|
$296.14 M
|
$139.48 M
|
$97.47 M
|
$62.08 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$92.07 M
|
$119.03 M
|
$174.05 M
|
$153.05 M
|
$160.79 M
|
$67.57 M
|
$37.60 M
|
$29.13 M
|
$20.99 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$524.87 M
|
$582.22 M
|
$724.97 M
|
$620.92 M
|
$602.99 M
|
$363.70 M
|
$177.07 M
|
$126.60 M
|
$83.07 M
|
| Cost And Expenses |
$536.58 M
|
$597.63 M
|
$747.19 M
|
$782.73 M
|
$674.66 M
|
$372.52 M
|
$181.59 M
|
$129.36 M
|
$83.51 M
|
| Interest Income |
$40.24 M
|
$71.81 M
|
$86.99 M
|
$28.09 M
|
$439.00 K
|
$2.84 M
|
$8.51 M
|
$2.54 M
|
$638.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$11.68 M
|
$14.56 M
|
$19.45 M
|
$15.49 M
|
$11.98 M
|
$8.81 M
|
$4.52 M
|
$2.76 M
|
$432.00 K
|
| EBITDA |
-$456.34 M |
-$508.86 M |
-$641.55 M |
$848.56 M |
$432.73 M |
-$287.34 M |
-$168.98 M |
-$115.94 M |
-$80.37 M |
| EBITDA Ratio |
-6.66
|
-6.86
|
-7.44
|
0.53
|
0.4
|
-3.76
|
-20.89
|
-10.87
|
-29.68
|
| Operating Income Ratio |
-6.83
|
-7.05
|
-7.67
|
0.52
|
0.38
|
-3.88
|
-21.44
|
-11.13
|
-29.84
|
| Total Other Income/Expenses Net |
$30.25 M
|
$316.00 K
|
$32.81 M
|
-$78.79 M
|
$129.05 M
|
-$2.46 M
|
-$1.03 M
|
$2.33 M
|
$21.00 K
|
| Income Before Tax |
-$437.77 M
|
-$523.11 M
|
-$628.19 M
|
$754.28 M
|
$549.80 M
|
-$298.61 M
|
-$174.53 M
|
-$116.36 M
|
-$80.78 M
|
| Income Before Tax Ratio |
-6.39
|
-7.05
|
-7.29
|
0.47
|
0.5
|
-3.91
|
-21.57
|
-10.91
|
-29.83
|
| Income Tax Expense |
$217.00 K
|
-$1.15 M
|
-$13.08 M
|
$238.44 M
|
$21.22 M
|
$54.00 K
|
$154.00 K
|
-$480.00 K
|
-$10.92 M
|
| Net Income |
-$437.99 M
|
-$521.96 M
|
-$615.06 M
|
$515.84 M
|
$528.58 M
|
-$298.67 M
|
-$174.68 M
|
-$115.88 M
|
-$69.85 M
|
| Net Income Ratio |
-6.39
|
-7.03
|
-7.14
|
0.32
|
0.48
|
-3.91
|
-21.59
|
-10.86
|
-25.79
|
| EPS |
-3.16 |
-3.83 |
-4.59 |
3.89 |
4.07 |
-2.51 |
-1.62 |
-1.2 |
-10.02 |
| EPS Diluted |
-3.16 |
-3.83 |
-4.59 |
3.83 |
3.96 |
-2.51 |
-1.62 |
-1.2 |
-10.02 |
| Weighted Average Shares Out |
$138.52 M
|
$136.25 M
|
$134.13 M
|
$132.61 M
|
$129.88 M
|
$119.16 M
|
$107.65 M
|
$96.91 M
|
$6.97 M
|
| Weighted Average Shares Out Diluted |
$138.52 M
|
$136.25 M
|
$134.13 M
|
$134.81 M
|
$133.44 M
|
$119.16 M
|
$107.65 M
|
$96.91 M
|
$6.97 M
|
| Link |
|
|
|
|
|
|
|
|
|
